Prescient Therapeutics Ltd (PTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Prescient Therapeutics Ltd (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8000
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a clinical stage oncology company that develops novel drugs for the treatment of solid and hematological cancers. The company’s lead drug candidate includes PTX-200, a potent small molecule inhibitor of the AKT pathway that is used in the development of various cancers, including ovarian and breast cancer as well as hematologic cancers such as acute myeloid leukemia; PTX-100, a drug that is used to kill cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). It develops immunotherapeutic products based on its Co-X-Gene technology platform. Prescient Therapeutics is headquartered in Melbourne, Victoria, Australia.

Prescient Therapeutics Ltd (PTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Prescient Therapeutics Enter into Collaboration with US-Based Drug Development Company 10
Equity Offering 11
Prescient Therapeutics Raises USD3.8 Million in Second and Final Tranche of Private Placement of Shares 11
Prescient Therapeutics Raises USD1.3 Million in First Tranche of Private placement of Shares 12
Prescient Therapeutics to Raise USD2.5 Million in Rights Offering of Shares 13
Virax Announces Private Placement Of Shares For US$2.7 Million 14
Virax Completes Private Placement Of Units 15
Virax Announces Private Placement Of Shares For Up To US$2.3 Million 16
Acquisition 17
Virax Acquires Pathway Oncology 17
Virax Acquires AKTivate Therapeutics and TCN-P Cancer Drug 18
Prescient Therapeutics Ltd – Key Competitors 19
Prescient Therapeutics Ltd – Key Employees 20
Prescient Therapeutics Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Product Approvals 22
Sep 04, 2017: Prescient to Resume Clinical Trial of PTX-200 in AML 22
May 01, 2017: FDA Grants Orphan Drug Designation for PTX-200 in Acute Myeloid Leukemia 23
Clinical Trials 24
Aug 30, 2018: Prescient Therapeutics: PTX-200 AML Study Expanded 24
Apr 10, 2018: PTX-200 Phase 1b Breast Cancer Trial Results Prescients Most Significant Clinical Milestone to Date 25
Dec 11, 2017: Prescient Therapeutics: Clinical Hold Lifted on PTX-200 Breast Cancer Trial 27
Nov 06, 2017: Prescient to Resume Clinical Trial of PTX-200 in Ovarian Cancer 28
May 29, 2017: Prescient Therapeutics Provides Update on Clinical Trials of PTX-200 29
Other Significant Developments 30
Jul 03, 2018: Prescient Therapeutics: PTXO Options Update 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Prescient Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Prescient Therapeutics Enter into Collaboration with US-Based Drug Development Company 10
Prescient Therapeutics Raises USD3.8 Million in Second and Final Tranche of Private Placement of Shares 11
Prescient Therapeutics Raises USD1.3 Million in First Tranche of Private placement of Shares 12
Prescient Therapeutics to Raise USD2.5 Million in Rights Offering of Shares 13
Virax Announces Private Placement Of Shares For US$2.7 Million 14
Virax Completes Private Placement Of Units 15
Virax Announces Private Placement Of Shares For Up To US$2.3 Million 16
Virax Acquires Pathway Oncology 17
Virax Acquires AKTivate Therapeutics and TCN-P Cancer Drug 18
Prescient Therapeutics Ltd, Key Competitors 19
Prescient Therapeutics Ltd, Key Employees 20
Prescient Therapeutics Ltd, Subsidiaries 21

List of Figures
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Prescient Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Prescient Therapeutics Ltd (PTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Red Electrica Corporacion SA (REE):企業の財務・戦略的SWOT分析
    Red Electrica Corporacion SA (REE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Spicers Ltd:企業の戦略的SWOT分析
    Spicers Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Rexel S.A.:戦略・SWOT・企業財務分析
    Rexel S.A. - Strategy, SWOT and Corporate Finance Report Summary Rexel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • The Medicines Company (MDCO)-医療機器分野:企業M&A・提携分析
    Summary The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company’s product portfolio comprises marketed products, namely, Angiomax (bivalirudin), Orbactiv (oritavancin), Minocin (minocycl …
  • Medifast, Inc. (MED):企業の財務・戦略的SWOT分析
    Medifast, Inc. (MED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Kkr Financial Holdings Llc
    Kkr Financial Holdings Llc - Strategy, SWOT and Corporate Finance Report Summary Kkr Financial Holdings Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Lorain-Medina Rural Electric Cooperative Inc:企業の戦略的SWOT分析
    Lorain-Medina Rural Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • UDG Healthcare Plc (UDG):企業の財務・戦略的SWOT分析
    UDG Healthcare Plc (UDG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BioMar Group AS:企業の戦略的SWOT分析
    BioMar Group AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • InvitroCue Ltd (IVQ):製薬・医療:M&Aディール及び事業提携情報
    Summary InvitroCue Ltd (InvitroCue), formerly Bunuru Corporation Ltd, is a provider of bio-analytic solutions. The company provides digital pathology services such as digitization, sample preparation, staining, computer aided diagnosis and consultation, telepathology, automated reporting and image a …
  • Alembic Pharmaceuticals Ltd (APLLTD):製薬・医療:M&Aディール及び事業提携情報
    Summary Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company’s active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antib …
  • Sao Martinho SA (SMTO3):企業の財務・戦略的SWOT分析
    Sao Martinho SA (SMTO3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Kadmon Corp LLC-製薬・医療分野:企業M&A・提携分析
    Summary Kadmon Corp LLC (Kadmon) is a biopharmaceutical company that offers products and related services for the management and treatment of hepatitis C. The company also develops therapies for metabolic and serious diseases. Its products include ribavirin, USP Tablets, ribavirin capsules, phenterm …
  • Shutterfly Inc:企業の戦略的SWOT分析
    Shutterfly Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Silgan Holdings Inc.:企業の戦略・SWOT・財務情報
    Silgan Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Silgan Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Publix Super Markets, Inc.:企業の戦略・SWOT・財務分析
    Publix Super Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Publix Super Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Carraro Spa:戦略・SWOT・企業財務分析
    Carraro Spa - Strategy, SWOT and Corporate Finance Report Summary Carraro Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • SandRidge Energy, Inc. (SD)-石油・ガス分野:企業M&A・提携分析
    Summary SandRidge Energy, Inc. (SandRidge) is an upstream energy company. It develops, explores for, and produces oil and natural gas in the Mid-Continent and Rockies regions of the US. In Mid-Continent, the company operates assets in Oklahoma and Kansas. In Rockies, SandRidge operates assets within …
  • United International Enterprises Limited:企業の戦略・SWOT・財務情報
    United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report Summary United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Heidelberg Pharma AG (HPHA):企業の財務・戦略的SWOT分析
    Heidelberg Pharma AG (HPHA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆